Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 21 entries
Sorted by: Best Match Show Resources per page
Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study.

Contemporary oncology (Poznan, Poland)

Kos-Kudła B.
PMID: 26793016
Contemp Oncol (Pozn). 2015;19(5):345-9. doi: 10.5114/wo.2015.56006. Epub 2015 Dec 22.

Somatostatin analogs (SSAs), including lanreotide, play a fundamental role in treatment of neuroendocrine tumors (NETs) of the gastrointestinal tract. SSAs control the clinical symptoms and are the treatment of choice in functioning NETs. Data indicating that SSAs have anti-proliferative...

Cite
Kos-Kudła B. Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study. Contemp Oncol (Pozn). 2015;19(5):345-9doi: 10.5114/wo.2015.56006.
Kos-Kudła, B. (2015). Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study. Contemporary oncology (Poznan, Poland), 19(5), 345-9. https://doi.org/10.5114/wo.2015.56006
Kos-Kudła, Beata. "Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study." Contemporary oncology (Poznan, Poland) vol. 19,5 (2015): 345-9. doi: https://doi.org/10.5114/wo.2015.56006
Kos-Kudła B. Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study. Contemp Oncol (Pozn). 2015;19(5):345-9. doi: 10.5114/wo.2015.56006. Epub 2015 Dec 22. PMID: 26793016; PMCID: PMC4709401.
Copy Download .nbib Format: NLM
NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.

Endocrine connections

Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B.
PMID: 30865931
Endocr Connect. 2019 Mar 01; doi: 10.1530/EC-19-0030. Epub 2019 Mar 01.

INTRODUCTION: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology.AIM(S): Independently validate NETest to diagnose GEP-NETs and identify progression in a tertiary referral center.MATERIALS AND METHODS:...

Cite
Malczewska A, Witkowska M, Makulik K, et al. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect. 2019;doi: 10.1530/EC-19-0030.
Malczewska, A., Witkowska, M., Makulik, K., Bocian, A., Walter, A., Pilch-Kowalczyk, J., Zajęcki, W., Bodei, L., Oberg, K. E., & Kos-Kudła, B. (2019). NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocrine connections, . https://doi.org/10.1530/EC-19-0030
Malczewska, Anna, et al. "NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging." Endocrine connections vol. (2019). doi: https://doi.org/10.1530/EC-19-0030
Malczewska A, Witkowska M, Makulik K, Bocian A, Walter A, Pilch-Kowalczyk J, Zajęcki W, Bodei L, Oberg KE, Kos-Kudła B. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr Connect. 2019 Mar 01; doi: 10.1530/EC-19-0030. Epub 2019 Mar 01. PMID: 30865931; PMCID: PMC6479193.
Copy Download .nbib Format: NLM
ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours.

Journal of neuroendocrinology

Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A.
PMID: 34693574
J Neuroendocrinol. 2021 Sep 15;e13044. doi: 10.1111/jne.13044. Epub 2021 Sep 15.

This expert consensus document represents an initiative by the European Neuroendocrine Tumor Society (ENETS) to provide guidance for synoptic reporting of radiological examinations critical to the diagnosis, grading, staging and treatment of neuroendocrine neoplasms (NENs). Template drafts for initial...

Cite
Dromain C, Vullierme MP, Hicks RJ, et al. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. J Neuroendocrinol. 2021;e13044doi: 10.1111/jne.13044.
Dromain, C., Vullierme, M. P., Hicks, R. J., Prasad, V., O'Toole, D., de Herder, W. W., Pavel, M., Faggiano, A., Kos-Kudla, B., Öberg, K., Krejs, G. J., Grande, E., Niederle, B., & Sundin, A. (2021). ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. Journal of neuroendocrinology, e13044. https://doi.org/10.1111/jne.13044
Dromain, Clarisse, et al. "ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours." Journal of neuroendocrinology vol. (2021): e13044. doi: https://doi.org/10.1111/jne.13044
Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. J Neuroendocrinol. 2021 Sep 15;e13044. doi: 10.1111/jne.13044. Epub 2021 Sep 15. PMID: 34693574.
Copy Download .nbib Format: NLM
The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

Londzin-Olesik M, Kos-Kudla B, Karpe J, Nowak A, Nowak M.
PMID: 33157557
Exp Clin Endocrinol Diabetes. 2021 Oct;129(10):762-769. doi: 10.1055/a-1274-0998. Epub 2020 Nov 06.

BACKGROUND AND STUDY AIMS: Thyroid-associated orbitopathy, the most common extrathyroidal manifestation of Graves' disease, is an autoimmune inflammation of orbital soft tissue. We report the study assessing the effect of immunosuppressive treatment with methylprednisolone on selected antioxidant parameters in...

Cite
Londzin-Olesik M, Kos-Kudla B, Karpe J, et al. The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy. Exp Clin Endocrinol Diabetes. 2020;129(10):762-769doi: 10.1055/a-1274-0998.
Londzin-Olesik, M., Kos-Kudla, B., Karpe, J., Nowak, A., & Nowak, M. (2021). The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 129(10), 762-769. https://doi.org/10.1055/a-1274-0998
Londzin-Olesik, Magdalena, et al. "The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy." Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association vol. 129,10 (2021): 762-769. doi: https://doi.org/10.1055/a-1274-0998
Londzin-Olesik M, Kos-Kudla B, Karpe J, Nowak A, Nowak M. The Effect of Immunosuppression on Selected Antioxidant Parameters in Patients with Graves' Disease with Active Thyroid-Associated Orbitopathy. Exp Clin Endocrinol Diabetes. 2021 Oct;129(10):762-769. doi: 10.1055/a-1274-0998. Epub 2020 Nov 06. PMID: 33157557.
Copy Download .nbib Format: NLM
Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study.

Endokrynologia Polska

Bolanowski M, Hubalewska-Dydejczyk A, Kos-Kudła B, Ruchała M, Witek P, Zgliczyński W, Houchard A, Bartmańska M.
PMID: 34647602
Endokrynol Pol. 2021;72(5):512-519. doi: 10.5603/EP.a2021.0075. Epub 2021 Oct 14.

INTRODUCTION: Patients with acromegaly have substantially reduced quality of life (QoL). This study evaluated QoL in patients with acromegaly treated with lanreotide autogel.MATERIAL AND METHODS: This was a prospective, non-interventional, observational, multi-centre study conducted in Poland (NCT02396966). We included...

Cite
Bolanowski M, Hubalewska-Dydejczyk A, Kos-Kudła B, et al. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study. Endokrynol Pol. 2021;72(5):512-519doi: 10.5603/EP.a2021.0075.
Bolanowski, M., Hubalewska-Dydejczyk, A., Kos-Kudła, B., Ruchała, M., Witek, P., Zgliczyński, W., Houchard, A., & Bartmańska, M. (2021). Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study. Endokrynologia Polska, 72(5), 512-519. https://doi.org/10.5603/EP.a2021.0075
Bolanowski, Marek, et al. "Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study." Endokrynologia Polska vol. 72,5 (2021): 512-519. doi: https://doi.org/10.5603/EP.a2021.0075
Bolanowski M, Hubalewska-Dydejczyk A, Kos-Kudła B, Ruchała M, Witek P, Zgliczyński W, Houchard A, Bartmańska M. Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study. Endokrynol Pol. 2021;72(5):512-519. doi: 10.5603/EP.a2021.0075. Epub 2021 Oct 14. PMID: 34647602.
Copy Download .nbib Format: NLM
LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis.

Contemporary oncology (Poznan, Poland)

Orlewska E, Bednarczuk T, Kaminski G, Kos-Kudla B.
PMID: 25784845
Contemp Oncol (Pozn). 2014;18(6):442-7. doi: 10.5114/wo.2014.47908. Epub 2014 Dec 31.

AIM OF THE STUDY: To examine characteristics and treatment patterns of symptomatic neuroendocrine tumors (NETs) patients who received lanreotide Autogel 120 mg (ATG120) administered as part of routine clinical practice.MATERIAL AND METHODS: Lanro-NET is a national, multicenter, non-interventional, observational...

Cite
Orlewska E, Bednarczuk T, Kaminski G, et al. LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis. Contemp Oncol (Pozn). 2014;18(6):442-7doi: 10.5114/wo.2014.47908.
Orlewska, E., Bednarczuk, T., Kaminski, G., Kos-Kudla, B. (2014). LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis. Contemporary oncology (Poznan, Poland), 18(6), 442-7. https://doi.org/10.5114/wo.2014.47908
Orlewska, Ewa, et al. "LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis." Contemporary oncology (Poznan, Poland) vol. 18,6 (2014): 442-7. doi: https://doi.org/10.5114/wo.2014.47908
Orlewska E, Bednarczuk T, Kaminski G, Kos-Kudla B. LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis. Contemp Oncol (Pozn). 2014;18(6):442-7. doi: 10.5114/wo.2014.47908. Epub 2014 Dec 31. PMID: 25784845; PMCID: PMC4355663.
Copy Download .nbib Format: NLM
The Safety and Efficacy of the Repeated PRRT with [.

International journal of endocrinology

Zemczak A, Gut P, Pawlak D, Kołodziej M, Królicki L, Kos-Kudła B, Ruchała M, Kamiński G, Kunikowska J.
PMID: 33552155
Int J Endocrinol. 2021 Jan 23;2021:6615511. doi: 10.1155/2021/6615511. eCollection 2021.

PURPOSE: The peptide receptor radionuclide therapy (PRRT) is a treatment option for patients with disseminated, inoperable G1 and G2 neuroendocrine tumours (NETs). The study aims to evaluate the safety, efficacy, and progression-free survival (PFS) of patients after retreatment (R-PRRT)...

Cite
Zemczak A, Gut P, Pawlak D, et al. The Safety and Efficacy of the Repeated PRRT with [. Int J Endocrinol. 2021;2021:6615511doi: 10.1155/2021/6615511.
Zemczak, A., Gut, P., Pawlak, D., Kołodziej, M., Królicki, L., Kos-Kudła, B., Ruchała, M., Kamiński, G., & Kunikowska, J. (2021). The Safety and Efficacy of the Repeated PRRT with [. International journal of endocrinology, 20216615511. https://doi.org/10.1155/2021/6615511
Zemczak, Anna, et al. "The Safety and Efficacy of the Repeated PRRT with [." International journal of endocrinology vol. 2021 (2021): 6615511. doi: https://doi.org/10.1155/2021/6615511
Zemczak A, Gut P, Pawlak D, Kołodziej M, Królicki L, Kos-Kudła B, Ruchała M, Kamiński G, Kunikowska J. The Safety and Efficacy of the Repeated PRRT with [. Int J Endocrinol. 2021 Jan 23;2021:6615511. doi: 10.1155/2021/6615511. eCollection 2021. PMID: 33552155; PMCID: PMC7847334.
Copy Download .nbib Format: NLM
Thyroid diseases in pregnancy: guidelines of the Polish Society of Endocrinology [Choroby tarczycy w ciąży: zalecenia postępowania Polskiego Towarzystwa Endokrynologicznego].

Endokrynologia Polska

Hubalewska-Dydejczyk A, Trofimiuk-Müldner M, Ruchala M, Lewiński A, Bednarczuk T, Zgliczyński W, Syrenicz A, Kos-Kudla B, Jarząb B, Gietka-Czernel M, Szczepanek-Parulska E, Krajewska J, Andrysiak-Mamos E, Zygmunt A, Karbownik-Lewińska M.
PMID: 34855189
Endokrynol Pol. 2021;72(5):425-488. doi: 10.5603/EP.a2021.0089.

Appropriate care of pregnant women with coexisting thyroid dysfunction is still a subject of much controversy. In recent years, there has been a dynamic increase in the number of scientific reports on the diagnosis and treatment of thyroid diseases...

Cite
Hubalewska-Dydejczyk A, Trofimiuk-Müldner M, Ruchala M, et al. Thyroid diseases in pregnancy: guidelines of the Polish Society of Endocrinology [Choroby tarczycy w ciąży: zalecenia postępowania Polskiego Towarzystwa Endokrynologicznego]. Endokrynol Pol. 2021;72(5):425-488doi: 10.5603/EP.a2021.0089.
Hubalewska-Dydejczyk, A., Trofimiuk-Müldner, M., Ruchala, M., Lewiński, A., Bednarczuk, T., Zgliczyński, W., Syrenicz, A., Kos-Kudla, B., Jarząb, B., Gietka-Czernel, M., Szczepanek-Parulska, E., Krajewska, J., Andrysiak-Mamos, E., Zygmunt, A., & Karbownik-Lewińska, M. (2021). Thyroid diseases in pregnancy: guidelines of the Polish Society of Endocrinology [Choroby tarczycy w ciąży: zalecenia postępowania Polskiego Towarzystwa Endokrynologicznego]. Endokrynologia Polska, 72(5), 425-488. https://doi.org/10.5603/EP.a2021.0089
Hubalewska-Dydejczyk, Alicja, et al. "Thyroid diseases in pregnancy: guidelines of the Polish Society of Endocrinology [Choroby tarczycy w ciąży: zalecenia postępowania Polskiego Towarzystwa Endokrynologicznego]." Endokrynologia Polska vol. 72,5 (2021): 425-488. doi: https://doi.org/10.5603/EP.a2021.0089
Hubalewska-Dydejczyk A, Trofimiuk-Müldner M, Ruchala M, Lewiński A, Bednarczuk T, Zgliczyński W, Syrenicz A, Kos-Kudla B, Jarząb B, Gietka-Czernel M, Szczepanek-Parulska E, Krajewska J, Andrysiak-Mamos E, Zygmunt A, Karbownik-Lewińska M. Thyroid diseases in pregnancy: guidelines of the Polish Society of Endocrinology [Choroby tarczycy w ciąży: zalecenia postępowania Polskiego Towarzystwa Endokrynologicznego]. Endokrynol Pol. 2021;72(5):425-488. doi: 10.5603/EP.a2021.0089. PMID: 34855189.
Copy Download .nbib Format: NLM
Diurnal rhythm of serum melatonin, ACTH and cortisol in asthma patients with long term glucocorticoid treatment.

Endocrine regulations

Kos-Kudla B, Ostrowska Z, Marek B, Ciesielska-Kopacz N, Kajdaniuk D, Kudla M, Buntner B.
PMID: 10931648
Endocr Regul. 1997 Mar;31(1):47-54.

Forty one patients (21 women and 20 men aged 35 to 45 years), with bronchial asthma were divided into two groups: those treated with glucocorticoids (with an equivalent daily dose of 8 mg prednisone) and those receiving no glucocorticoid...

Cite
Kos-Kudla B, Ostrowska Z, Marek B, et al. Diurnal rhythm of serum melatonin, ACTH and cortisol in asthma patients with long term glucocorticoid treatment. Endocr Regul. 1997;31(1):47-54
Kos-Kudla, B., Ostrowska, Z., Marek, B., Ciesielska-Kopacz, N., Kajdaniuk, D., Kudla, M., & Buntner, B. (1997). Diurnal rhythm of serum melatonin, ACTH and cortisol in asthma patients with long term glucocorticoid treatment. Endocrine regulations, 31(1), 47-54.
Kos-Kudla, et al. "Diurnal rhythm of serum melatonin, ACTH and cortisol in asthma patients with long term glucocorticoid treatment." Endocrine regulations vol. 31,1 (1997): 47-54.
Kos-Kudla B, Ostrowska Z, Marek B, Ciesielska-Kopacz N, Kajdaniuk D, Kudla M, Buntner B. Diurnal rhythm of serum melatonin, ACTH and cortisol in asthma patients with long term glucocorticoid treatment. Endocr Regul. 1997 Mar;31(1):47-54. PMID: 10931648.
Copy Download .nbib Format: NLM
Iatrogenic Adrenal Cortex Failure in Patients with Steroid Dependent Asthma in Relation to Different Methods of Glucocorticoid Treatment.

Endocrine regulations

Kos-Kudla B.
PMID: 10330524
Endocr Regul. 1998 Jun;32(2):99-106.

OBJECTIVE: To evaluate and compare the degree of adrenal cortex suppression in patients receiving long term treatment with different formulas and doses of glucocorticoids (GC) which is of considerable diagnostic and therapeutic importance. METHODS: A total of 97 subjects...

Cite
Kos-Kudla B. Iatrogenic Adrenal Cortex Failure in Patients with Steroid Dependent Asthma in Relation to Different Methods of Glucocorticoid Treatment. Endocr Regul. 1998;32(2):99-106
Kos-Kudla, B. (1998). Iatrogenic Adrenal Cortex Failure in Patients with Steroid Dependent Asthma in Relation to Different Methods of Glucocorticoid Treatment. Endocrine regulations, 32(2), 99-106.
Kos-Kudla. "Iatrogenic Adrenal Cortex Failure in Patients with Steroid Dependent Asthma in Relation to Different Methods of Glucocorticoid Treatment." Endocrine regulations vol. 32,2 (1998): 99-106.
Kos-Kudla B. Iatrogenic Adrenal Cortex Failure in Patients with Steroid Dependent Asthma in Relation to Different Methods of Glucocorticoid Treatment. Endocr Regul. 1998 Jun;32(2):99-106. PMID: 10330524.
Copy Download .nbib Format: NLM
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors.

Neuroendocrinology

Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW.
PMID: 28253514
Neuroendocrinology. 2017;105(3):245-254. doi: 10.1159/000461583. Epub 2017 Mar 02.

No abstract available.

Cite
Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):245-254doi: 10.1159/000461583.
Kaltsas, G., Caplin, M., Davies, P., Ferone, D., Garcia-Carbonero, R., Grozinsky-Glasberg, S., Hörsch, D., Tiensuu Janson, E., Kianmanesh, R., Kos-Kudla, B., Pavel, M., Rinke, A., Falconi, M., de Herder, W. W. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 105(3), 245-254. https://doi.org/10.1159/000461583
Kaltsas, Gregory, et al. "ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors." Neuroendocrinology vol. 105,3 (2017): 245-254. doi: https://doi.org/10.1159/000461583
Kaltsas G, Caplin M, Davies P, Ferone D, Garcia-Carbonero R, Grozinsky-Glasberg S, Hörsch D, Tiensuu Janson E, Kianmanesh R, Kos-Kudla B, Pavel M, Rinke A, Falconi M, de Herder WW. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):245-254. doi: 10.1159/000461583. Epub 2017 Mar 02. PMID: 28253514; PMCID: PMC5637287.
Copy Download .nbib Format: NLM
ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation.

Neuroendocrinology

Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP.
PMID: 28222443
Neuroendocrinology. 2017;105(3):310-319. doi: 10.1159/000458155. Epub 2017 Feb 17.

No abstract available.

Cite
Knigge U, Capdevila J, Bartsch DK, et al. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017;105(3):310-319doi: 10.1159/000458155.
Knigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., Pascher, A., Reed, N., Sundin, A., Vullierme, M. P. (2017). ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology, 105(3), 310-319. https://doi.org/10.1159/000458155
Knigge, U, et al. "ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation." Neuroendocrinology vol. 105,3 (2017): 310-319. doi: https://doi.org/10.1159/000458155
Knigge U, Capdevila J, Bartsch DK, Baudin E, Falkerby J, Kianmanesh R, Kos-Kudla B, Niederle B, Nieveen van Dijkum E, O'Toole D, Pascher A, Reed N, Sundin A, Vullierme MP. ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. Neuroendocrinology. 2017;105(3):310-319. doi: 10.1159/000458155. Epub 2017 Feb 17. PMID: 28222443.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 21 entries